---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-061208"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2026-05-14T20:23:01+00:00"
generated_at: "2026-05-14T20:25:49.491048+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Fortress Biotech Q1 net income $108.4M; PRV sale for $205M and ZYCUBO approval drive results

## Summary
- Net income $108.4M ($3.44 basic EPS) vs net loss $12.7M in Q1 2025; revenue $16.0M up from $13.1M.
- Subsidiary Cyprium sold Rare Pediatric Disease PRV for $205M in March 2026; ZYCUBO approved for Menkes disease.
- Debt reduced: prepaid Oaktree loan to $15M outstanding; cash increased to $255.8M from $79.4M.
- Checkpoint acquisition by Sun Pharma gives Fortress ~$28M upfront + 2.5% royalty on UNLOXCYT sales.
- Journey Medical's Emrosi launched; payer access expanded to 85% of US commercial lives.

## SEC filing metadata
- accession: 0001104659-26-061208
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2026-05-14T20:23:01+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000110465926061208/0001104659-26-061208-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000110465926061208/fbio-20260514x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-061208
- JSON: https://secwatch.observer/filing/0001104659-26-061208.json
- Plain text: https://secwatch.observer/filing/0001104659-26-061208.txt

## Key facts
- Earnings Releases
  Fortress Biotech, Inc. reported the first quarter ended March 31, 2026 results: net income $108.4 million, or $3.44 per common share (basic) and $2.82 per common share (diluted).
  - Period: the first quarter ended March 31, 2026
  - Net income: $108.4 million, or $3.44 per common share (basic) and $2.82 per common share (diluted)
  - Result: reported results
  source text: Fortress’ consolidated net income attributable to common stockholders for the first quarter of 2026 was $108.4 million, or $3.44 per common share (basic) and $2.82 per common share (diluted)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1429260/000110465926061208/0001104659-26-061208-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.